Skip to main content

6-K

COSCIENS Biopharma Inc. (CSCIF)

6-K 2023-06-14 For: 2023-06-14
View Original
Added on April 06, 2026

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549


FORM6-K


REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934


For the month of June 2023

Commission File Number: 001-38064

AeternaZentaris Inc.

(Translation of registrant’s name into English)

c/oNorton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Exhibits 99.1 and 99.2 included with this report on Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561 and No. 333-200834), Forms F-3 (No. 333-254680) and Forms F-1 (No.333-239264, No. 333-248561 and No. 333-239019) and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

DOCUMENTSINDEX

Exhibit Description
99.1 Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102
| \(2\) |

| --- |

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.
Date:<br> June 14, 2023 By: /s/ Klaus Paulini
Klaus<br> Paulini
President<br> and Chief Executive Officer
| \(3\) |

| --- |


Exhibit99.1


AETERNAZENTARIS INC.

Reportof Voting Results

SubmittedPursuant to

Section11.3 of National Instrument 51-102 – Continuous Disclosure Obligations

June14, 2023

In accordance with Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general and special meeting of shareholders of Aeterna Zentaris Inc. (the “Company”) held on June 14, 2023 via live audio webcast. Each of the matters is described in greater detail in the Company’s management information circular dated May 9, 2023 (the “Circular”).

(a) The<br> five nominees set forth in the Circular were elected as directors of the Company to hold office until the close of the next annual<br> meeting of the Company’s shareholders or until their successors are duly elected or appointed. The following are the voting<br> results on this matter:
FOR % FOR AGAINST % AGAINST
--- --- --- --- --- --- --- --- --- --- ---
Peter Edwards 401,912 68.94 % 181,057 31.06 %
Carolyn Egbert 296,499 50.86 % 286,470 49.14 %
Gilles Gagnon 402,690 69.08 % 180,279 30.92 %
Dr. Klaus Paulini 317,211 54.41 % 265,758 45.59 %
Dennis Turpin 298,514 51.21 % 284,455 48.79 %
(b) Deloitte<br> LLP was appointed as the Company’s auditors and the directors were authorized to fix the remuneration to be paid to the auditors.<br> The following are the voting results on this matter:
--- ---
FOR % FOR WITHHELD %WITHHELD
--- --- --- --- --- --- --- --- --- --- ---
Appointment of Auditors 1,157,809 83.18 % 234,119 16.82 %

Dated this 14^th^ day of June, 2023.

AETERNA ZENTARIS INC.
By: (signed)Giuliano La Fratta
Name: Giuliano La Fratta
Title: Chief Financial Officer